<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17157" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Lymphocytic Leukemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Puckett</surname>
            <given-names>Yana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chan</surname>
            <given-names>Onyee</given-names>
          </name>
          <aff>Un of AZ, Banner Un Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yana Puckett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Onyee Chan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17157.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute lymphocytic leukemia (ALL) is a malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. ALL accounts for approximately 2 percent of lymphoid neoplasms in the United States and occurs slightly more frequently in males than females and three times as frequently in Caucasians as in African Americans. Patients typically present with symptoms related to anemia, thrombocytopenia, and neutropenia due to the replacement of the bone marrow with the tumor. Symptoms can include fatigue, easy or spontaneous bruising and/or bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central nervous system (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. This activity examines when acute lymphocytic leukemia should be considered on differential diagnosis and how to properly evaluate it. This activity highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the epidemiology of acute lymphocytic leukemia.</p></list-item><list-item><p>Outline the exam findings typically seen in patients with acute lymphocytic leukemia.</p></list-item><list-item><p>Review the management of acute lymphocytic leukemia.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by acute lymphocytic leukemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17157&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17157">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17157.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acute lymphocytic leukemia (ALL) is a malignancy of B or T lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a typical disease pattern characteristic of acute lymphocytic leukemia. ALL accounts for approximately 2 percent of the lymphoid neoplasms diagnosed in the United States. Acute lymphocytic leukemia&#x000a0;occurs slightly more frequently in males than females and three times as frequently in Whites as in Blacks.&#x000a0;Patients with acute lymphocytic leukemia typically present with symptoms related to anemia, thrombocytopenia, and neutropenia due to the replacement of the bone marrow with the tumor. Symptoms can include fatigue, easy or spontaneous&#x000a0;bruising/bleeding,&#x000a0;and infections. B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild. Hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central nervous system (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure.<xref ref-type="bibr" rid="article-17157.r1">[1]</xref><xref ref-type="bibr" rid="article-17157.r2">[2]</xref><xref ref-type="bibr" rid="article-17157.r3">[3]</xref></p>
      </sec>
      <sec id="article-17157.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of acute lymphocytic leukemia is unknown. However, certain environmental factors have been implicated in the etiology of Acute Lymphocytic Leukemia, such as exposure to benzene, ionizing radiation, or previous exposure to chemotherapy or radiotherapy.</p>
        <p>Genomic studies have noted that somatic, polymorphic variants of ARD5B, IKZF1 (the gene encoding Ikaros), and CDKN2A are associated with an increased risk of ALL (odds ratio 1.3 to 1.9). Other rare germline mutations in PAX5, ETV6, and particularly p53 can also strongly predispose to the development of leukemia.</p>
        <p>Acute lymphoblastic leukemia is not considered a familial disease, and no screening programs have been developed to test for it in childhood.&#x000a0;</p>
      </sec>
      <sec id="article-17157.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>It is diagnosed in about 4000 people&#x000a0;in the United States each year, with the majority being under the age of 18. It is the most common malignancy of childhood. The peak age of diagnosis is between two and ten years of age. Acute Lymphocytic Leukemia&#x000a0;is more common in children with Trisomy 21 (Down syndrome), neurofibromatosis type 1, Bloom syndrome, and ataxia telangiectasia. All are common in children between two and three years of age. Prognosis is diminished in children when diagnosed in infants less than one year of age and in adults. It is more favorable in children. The association of the MLL gene in children at the 11q23 chromosome is associated with poor prognosis. Acute lymphocytic leukemia is a disease with low incidence overall in population studies. The incidence of acute lymphocytic leukemia is about 3.3 cases per 100,000 children.&#x000a0;Survival rates for ALL have improved dramatically since the 1980s, with a current five-year overall survival rate estimated at greater than 85 percent.</p>
      </sec>
      <sec id="article-17157.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Acute lymphocytic leukemia is thought to occur after damage to DNA causes lymphoid cells to undergo uncontrolled growth and spread throughout the body. Splenomegaly and hepatomegaly occur due to sequestration of platelets and lymphocytes in the spleen and liver; as the white blood cells are not typical, the spleen reacts to them by trying to remove them from the blood.<xref ref-type="bibr" rid="article-17157.r4">[4]</xref><xref ref-type="bibr" rid="article-17157.r5">[5]</xref><xref ref-type="bibr" rid="article-17157.r6">[6]</xref></p>
      </sec>
      <sec id="article-17157.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On peripheral blood smears of acute lymphocytic leukemia patients, lymphoblasts vary in size. Various CD cytokines must be tested to evaluate for what kind of acute lymphocytic leukemia the patient has developed</p>
      </sec>
      <sec id="article-17157.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common presenting symptoms of acute lymphocytic leukemia are nonspecific and may be difficult to distinguish from common, self-limited diseases of childhood. In a meta-analysis, more than half of children with childhood leukemia had at least one of the following five features on presentation: palpable liver, palpable spleen, pallor, fever, or bruising.&#x000a0;ALL patients typically present with symptoms of night sweats, easy bruising, skin pallor, unexplained lymphadenopathy, weakness, weight loss, hepatosplenomegaly, or difficulty breathing. Some patients may present with superior vena cava syndrome.&#x000a0;Bone pain, mental changes, and oliguria may also be present. ALL can also present with testicular enlargement, musculoskeletal pain, mediastinal mass, and incidentally found peripheral blood cell abnormalities.&#x000a0;</p>
      </sec>
      <sec id="article-17157.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Acute Lymphocytic Leukemia diagnosis should be explored initially with a laboratory evaluation consisting of a CBC, electrolyte and renal panel, and LDH level. Additionally, imaging, such as a chest x-ray for symptoms of shortness of breath, may be obtained. If abdominal fullness, tenderness, or abdominal mass are symptoms, then a CT scan of the abdomen and pelvis should be obtained. This can also help with the staging of the disease.</p>
        <p>NCCN diagnosis guidelines:</p>
        <list list-type="bullet">
          <list-item>
            <p>Have presence of more than 20% bone marrow lymphoblasts</p>
          </list-item>
          <list-item>
            <p>Hematoxylin and eosin-stained bone marrow clot and biopsy sections</p>
          </list-item>
          <list-item>
            <p>Morphology of bone marrow aspirate assessed with Wright/Giemsa</p>
          </list-item>
          <list-item>
            <p>Complete flow cytometric immunophenotyping</p>
          </list-item>
          <list-item>
            <p>Baseline evaluation of the leukemic clone</p>
          </list-item>
        </list>
        <p>Lumbar puncture is used to evaluate CNS involvement. The fluid is checked for the presence of lymphoblasts.</p>
      </sec>
      <sec id="article-17157.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Children who are suspected of having acute lymphocytic leukemia should be referred to a pediatric center that specializes in cancer for evaluation and treatment.</p>
        <p>For children with Acute Lymphocytic Leukemia, induction therapy consists of anthracycline, vincristine, 1-asparaginase, and a corticosteroid.</p>
        <p>Today consolidation therapy is widely used and includes therapy with a variety of chemotherapeutic drugs with good results.</p>
        <p>Maintenance therapy utilizes oral 6-mercaptopurine or methotrexate delivered once weekly or once monthly.&#x000a0;&#x000a0;Successful treatment of children with acute lymphocytic leukemia involves the administration of a multidrug regimen that is divided into several phases (i.e., induction, consolidation, and maintenance) and includes therapy directed to the central nervous system (CNS).</p>
        <p>Most treatment protocols take two to three years to complete.</p>
        <p>CNS prophylaxis is done via an intrathecal approach. Patients often require 8 to 16 intrathecal treatments.</p>
        <p>If the patient has Ph-chromosome positive ALL, the current treatment includes the use of tyrosine kinase inhibitors like imatinib, nilotinib, dasatinib, or ponatinib. Several trials have shown a good response to these agents.</p>
        <p>Stem cell transplantation can sometimes be used as a treatment in which a patient's normal source of blood cells (bone marrow) is replaced by healthy young blood cells (stem cells) from a healthy well-matched donor. However, with improvements in chemotherapy, the role of transplantation is declining in ALL.</p>
        <p>Recently CAR-T cell therapy has been investigated in ALL with excellent results. Several studies show high rates of remission. Unfortunately, CART is also associated with serious toxicity that includes cerebral edema and cytokine release syndrome, which can be fatal.</p>
        <p>All blood products must be irradiated prior to transfusion to prevent transfusion-related graft versus host disease, which is universally fatal.</p>
        <p>Splenectomy is rarely required for acute lymphocytic leukemia. Splenectomy can help boost platelet count but does not affect the outcome of leukemia itself. Splenectomy can be performed for severe symptoms that are not amenable to chemotherapy treatment, such as abdominal pain. Radiation can also be used in cases of enlarged spleen to try and reduce the size of the spleen in most cases.<xref ref-type="bibr" rid="article-17157.r7">[7]</xref><xref ref-type="bibr" rid="article-17157.r8">[8]</xref><xref ref-type="bibr" rid="article-17157.r9">[9]</xref></p>
        <p>Tumor lysis syndrome is a life-threatening complication that occurs in patients receiving chemotherapy. It is characterized by hyperuricemia, elevated potassium and phosphate, and decreased levels of calcium. Renal failure is invariably present.</p>
      </sec>
      <sec id="article-17157.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>B cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin&#x000a0;lymphoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17157.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Current World Health Organization Classification of ALL<xref ref-type="bibr" rid="article-17157.r10">[10]</xref></bold>
</p>
        <p>
<bold>B-lymphoblastic leukemia/lymphoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma, NOS</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);&#x000a0; BCR-ABL1</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); KMT2A rearranged</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);&#x000a0; ETV6-RUNX1</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with hyperdiploidy</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with hypodiploidy</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3);&#x000a0; IL3-IGH</p>
          </list-item>
          <list-item>
            <p>B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);&#x000a0; TCF3-PBX1</p>
          </list-item>
          <list-item>
            <p>Provisional entity: B-lymphoblastic leukemia/lymphoma,&#x000a0; BCR-ABL1-like</p>
          </list-item>
          <list-item>
            <p>Provisional entity: B-lymphoblastic leukemia/lymphoma with&#x000a0; iAMP21</p>
          </list-item>
        </list>
        <p>
<bold>T-lymphoblastic leukemia/lymphoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Provisional entity: Early T-cell precursor lymphoblastic leukemia</p>
          </list-item>
          <list-item>
            <p>Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17157.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Only about 30% of adults with ALL can be cured today. Criteria for good prognosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age of less than 30</p>
          </list-item>
          <list-item>
            <p>No abnormal cytogenetics</p>
          </list-item>
          <list-item>
            <p>WBC count less than 30,000</p>
          </list-item>
          <list-item>
            <p>Complete remission within 4 weeks</p>
          </list-item>
          <list-item>
            <p>High hyperdiploidy with 51&#x02013;65 chromosomes in children</p>
          </list-item>
          <list-item>
            <p>t(12;21)(p13;q22) in children</p>
          </list-item>
        </list>
        <p>
<bold>Poor prognostic factors include:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Age of more than 60</p>
          </list-item>
          <list-item>
            <p>Presence of abnormal cytogenetics (t(9:22), t(4:11)</p>
          </list-item>
          <list-item>
            <p>Failure to achieve remission within 4 weeks</p>
          </list-item>
          <list-item>
            <p>Precursor B-cells more than 100,000</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17157.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Despite improvements in supportive care, death resulting from treatment toxicity remains a challenge.&#x000a0;It is important to watch out for tumor lysis syndrome, which occurs when chemotherapy causes cancer cells to lyse, releasing certain intracellular elements such as potassium, calcium, uric acid, and phosphorus. These elements, in large numbers, result in toxicity that can often lead to renal failure. Pretreatment with fluids and steroids typically prevents Tumor Lysis Syndrome. However, if it occurs, aggressive fluid therapy is the treatment.&#x000a0;</p>
        <p>Even after treatment, acute lymphocytic leukemia can relapse. Relapses can occur as far back as 21 years. It is important to address other issues associated with cancer treatment in a young child, including providing psychological support to the child, parents, and family.&#x000a0;</p>
      </sec>
      <sec id="article-17157.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Like all malignancies, the management of acute leukemia is with an interprofessional team dedicated to the management of cancer patients; an interprofessional team includes an oncologist, an internist, an infectious disease expert, and a hematologist. The primary care provider and nurse practitioner may be responsible for follow-up after treatment and report back to the interprofessional team. These patients need close monitoring as they are prone to infections, coagulation dyscrasias, and relapse. Team conferences should be held while the patient is being treated, and any problems should be conveyed to the team.</p>
        <p>The pharmacist should educate the patient on chemotherapy medications, their adverse effects, and their benefits. The dietitian should encourage a healthy diet. To prevent infections, the nurse practitioner should encourage hand washing, washing of fruits and vegetables, and maintaining good personal hygiene.</p>
        <p>The oncology nurses should monitor the patient for adverse effects of the drug, including tumor lysis syndrome. Patients should be given consistent messages, and one should avoid offering unrealistic expectations. To improve outcomes, the team should keep updated on the latest clinical trials.</p>
        <p>Outcomes</p>
        <p>Despite improvements in supportive care, death resulting from treatment toxicity remains a challenge.&#x000a0;It is important to watch out for tumor lysis syndrome, which occurs when chemotherapy causes cancer cells to lyse, releasing certain intracellular elements such as potassium, calcium, uric acid, and phosphorus. These elements, in large numbers, result in toxicity that can often lead to renal failure. Pretreatment with fluids and steroids typically prevents tumor lysis syndrome. However, if it occurs, aggressive fluid therapy is the treatment.</p>
        <p>Even after treatment, acute lymphocytic leukemia can relapse. Relapses can occur as far back as 21 years. It is important to address other issues&#x000a0;associated with&#x000a0;cancer treatment in a young child, including providing psychological support to the child, parents, and family.&#x000a0;</p>
      </sec>
      <sec id="article-17157.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17157&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17157">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/acute-lymphocytic-leukemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17157">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17157/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17157">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17157.s16">
        <title>References</title>
        <ref id="article-17157.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Genetics and prognosis of ALL in children vs adults.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-145</page-range>
            <pub-id pub-id-type="pmid">30504302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>No free rides: management of toxicities of novel immunotherapies in ALL, including financial.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-34</page-range>
            <pub-id pub-id-type="pmid">30504288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liedtke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antibody-based therapies in patients with acute lymphoblastic leukemia.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-15</page-range>
            <pub-id pub-id-type="pmid">30504286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeRenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krenciute</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gottschalk</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2018</year>
            <month>May</month>
            <day>23</day>
            <volume>38</volume>
            <fpage>830</fpage>
            <page-range>830-837</page-range>
            <pub-id pub-id-type="pmid">30231350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Genetics and epigenetics of pediatric leukemia in the era of precision medicine.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30079227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valentin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grabow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davids</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The rise of apoptosis: targeting apoptosis in hematologic malignancies.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Sep</month>
            <day>20</day>
            <volume>132</volume>
            <issue>12</issue>
            <fpage>1248</fpage>
            <page-range>1248-1264</page-range>
            <pub-id pub-id-type="pmid">30012635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fathi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wieduwilt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cassaday</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coccia</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Damon</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Frankfurt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Klisovic</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kupfer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mattison</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubnitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uy</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ogba</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>1091</fpage>
            <page-range>1091-1102</page-range>
            <pub-id pub-id-type="pmid">28874594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radich</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Czuczman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Horning</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Houldsworth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wetzler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>NCCN task force report: molecular markers in leukemias and lymphomas.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>7 Suppl 4</volume>
            <fpage>S1</fpage>
            <page-range>S1-34, quiz S35-6</page-range>
            <pub-id pub-id-type="pmid">19635230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvarnas</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ballen</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Borate</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cassaday</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Coccia</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Damon</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Douer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Frankfurt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Klisovic</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kupfer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Uy</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute Lymphoblastic Leukemia, Version 2.2015.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>1240</fpage>
            <page-range>1240-79</page-range>
            <pub-id pub-id-type="pmid">26483064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17157.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2391</fpage>
            <page-range>2391-405</page-range>
            <pub-id pub-id-type="pmid">27069254</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
